Please assess the completion status of the following clinical trial:

Trial Title: Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A morphologically proven diagnosis of AML according to the WHO classification~* Serum creatinine \< 2N; AST and ALT \< 2.5N; total bilirubin \< 2N (unless related to the underlying disease).~* ECOG performance status 0 to 2.~* Women of child-bearing must use acceptable contraceptive methods, and must have a negative serum or urine pregnancy test within 2 weeks prior the beginning treatment on this trial.~* Must be able and willing to give written informed consent~Exclusion Criteria:~* Patients with M3-AML. Patient with AML following diagnosed myeloproliferation or patient with prior history of MDS known for more than 3 months. Patients with AML secondary to previous treatment with cytotoxic chemotherapy or radiotherapy (therapy-related AML).~* Patient presenting any diagnosis of uncontrolled or metastatic tumor.~* Patients with uncontrolled severe infection,

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- EMA+GM-CSF (Type: EXPERIMENTAL): * Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~* AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~* Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~* AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10.~* GM-CSF (LeucomaxR): 5 µg/kg/jour IV over 6 hours from day 1 to day 10.
- EMA without GM-CSF (Type: ACTIVE_COMPARATOR): * Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~* AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~* Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~* AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10.
- HD AraC+ GM-CSF (Type: EXPERIMENTAL): * AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5~* GM-CSF :5 µg/kg/d IV (6 hours) from day1 to day 5
- HD-AraC without GM-CSF (Type: ACTIVE_COMPARATOR): - AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5

Based on this trial design, predict the completion outcome and termination type (if applicable).